Preoperative selpercatinib induces major pathological response in a patient with stage IIIA, RET fusion-positive non-small cell lung cancer: A case report
This case highlights the potential of selpercatinib in the perioperative setting, suggesting that it induces tumor regression and enabling of curative surgery in early-stage RET fusion-positive NSCLC. Our findings support the further investigation of selpercatinib in early stages and provide a rationale for future treatment strategies of early-stage RET fusion-positive NSCLC patients.
Authors
- Arschang Valipour (ORCID: https://orcid.org/0000-0001-6574-1721)
- Maximilian J. Hochmair (ORCID: https://orcid.org/0000-0002-8673-2450)
- Stefan Watzka (ORCID: https://orcid.org/0000-0002-4149-4890)
- Hannah Fabikan
- Thomas Klikovits (ORCID: https://orcid.org/0000-0003-1012-0404)
- Kristina Breitenecker (ORCID: https://orcid.org/0000-0002-5334-6377)
- Christoph Weinlinger
- Dagmar Krenbek
Institutions
- Paracelsus Medical University (AT)
- Primary HealthCare (MT)
- Karl Landsteiner Society (AT)
- Institut für Lungenforschung (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Medicine
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1097/md.0000000000045554
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00